Vogenx Inc Common Stock

Vogenx, Inc. is a clinical-stage drug development company focused on therapeutics for metabolic conditions, including post-bariatric hypoglycemia (PBH) and gastroparesis. Its product candidates include Mizagliflozin, VGX-2857, and VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). The company serves healthcare providers, physicians, and third-party payors in the United States. Incorporated in 2021, it is based in Raleigh, North Carolina.